Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 12/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | FPR1 | P21462 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | GPR183 | P32249 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7030815 | 0.94 | SLC6A2 (0.37) | SLC6A2SLC6A4TACR1SCN9ANR3C1 | |
| SCHEMBL7506220 | 0.91 | TACR1 (0.48) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL7030232 | 0.91 | SLC6A4 (0.38) | SLC6A2SLC6A4TACR1SCN9ANR3C1 | |
| SCHEMBL7025688 | 0.91 | TACR1 (0.40) | TACR1SCN9ANR3C1CYP3A4FPR1 | |
| SCHEMBL7029279 | 0.91 | TACR1 (0.48) | TACR1NR3C1CYP3A4FPR1TACR3 | |
| SCHEMBL7022222 | 0.90 | HTR6 (0.43) | SLC6A2SLC6A4TACR1SCN9A | |
| SCHEMBL7022722 | 0.90 | TACR1 (0.41) | TACR1SCN9ANR3C1CYP3A4FPR1 | |
| SCHEMBL7022782 | 0.89 | TACR1 (0.38) | SLC6A2SLC6A4TACR1SCN9ANR3C1 | |
| SCHEMBL7028814 | 0.88 | TACR1 (0.47) | SLC6A2SLC6A4TACR1CHRNA7 | |
| SCHEMBL7022578 | 0.88 | TACR1 (0.40) | SLC6A2SLC6A4TACR1SCN9ANR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020002164-A1 | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO., INC. | 2002-01-03 | — | — | US | claimed |
| EP-0734381-B1 | MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2000-07-05 | — | — | EP | claimed |
| US-6048859-A | ANTIEMETIC AGENT | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | claimed |
| EP-0748320-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-12-18 | — | — | EP | claimed |
| WO-1995023798-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-09-08 | — | — | WO | claimed |
| US-6638930-B2 | Antiinflammatory agents, analgesics, antiasthmatics, antiemitics and calcium channel blockers for angina, hypertension or ischemia | MERCK & CO. INC. | 2003-10-28 | — | — | US | disclosed |
| EP-0748320-B1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020002164-A1 | Morpholine and thiomorpholine tachykinin receptor antagonists | MERCK & CO., INC. | 2002-01-03 | — | — | US | disclosed |
| US-6235735-B1 | AFTERTREATMENT OF RADIATION THERAPY | MERCK & CO., INC. | 2001-05-22 | — | — | US | disclosed |
| EP-0734381-B1 | MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2000-07-05 | — | — | EP | disclosed |
| US-6048859-A | ANTIEMETIC AGENT | MERCK & CO., INC. (US) | 2000-04-11 | — | — | US | disclosed |
| US-5922706-A | TREATING INFLAMMATORY DISEASES, PAIN OR MIGRAINE, ASTHMA AND EMESIS, AND CALCIUM CHANNEL BLOCKERS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS SUCH AS ANGINA, HYPERTENSION OR ISCHEMIA | MERCK & CO., INC. (US) | 1999-07-13 | — | — | US | disclosed |
| US-5716942-A | ADMINISTERING TO ANTAGONIZE EFFECT OF SUBSTANCE P AT RECEPTOR SITE, BLOCKADE NEUROKININ-1 RECEPTORS | MERCK & CO., INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5691336-A | ANTIINFLAMMATORY AGENTS; ANALGESICS; THERAPY OF ASTHMA, EMESIS | MERCK & CO., INC. (US) | 1997-11-25 | — | — | US | disclosed |
| US-5637699-A | CARDIOVASCULAR DISORDERS; ANTIINFLAMMATORY AGENT | MERCK & CO., INC. (US) | 1997-06-10 | — | — | US | disclosed |
| EP-0748320-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-12-18 | — | — | EP | disclosed |
| EP-0734381-A1 | MORPHOLINE AND THIOMORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1996-10-02 | — | — | EP | disclosed |
| US-5512570-A | Treatment of emesis with morpholine tachykinin receptor antagonists | MERCK & CO., INC. (US) | 1996-04-30 | — | — | US | disclosed |
| WO-1995023798-A1 | PRODRUGS OF MORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-09-08 | — | — | WO | disclosed |
| WO-1995016679-A1 | MORPHOLINE AND THIOMORPHOLINE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1995-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002164-A1 | Morpholine and thiomorpholine tachykinin receptor antagonists | TRPM7, TRPM2, TRPM5 | SLC6A2 1902/4885SLC6A4 885/4885TACR1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.